Source:http://linkedlifedata.com/resource/pubmed/id/17524073
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
2007-6-13
|
pubmed:abstractText |
African Americans (AA) have traditionally been thought to have higher immunologic risk than Caucasians (CA) for rejection and allograft loss. The impact of ethnicity on the outcome of simultaneous pancreas-kidney (SPK) transplant with basiliximab induction has not been reported. In this study, we retrospectively analyze the long-term results of 36 AA and 55 CA recipients of primary SPK. The actual patient survival rates of AA and CA groups were 91.7% vs. 90.1% at 1 year, 93.3% vs. 88.1% at 3 years, and 94.4% vs. 83.3% at 5 years. The actual kidney survival of AA and CA were 91.7% vs. 89.1% at 1 year, 90% vs. 81% at 3 years, and 83.3% vs. 75% at 5 years. The actual pancreas survival of AA and CA were 88.9% vs. 85.5% at 1 year, 83.3% vs. 78.6% at 3 years and 72.2% vs. 70.8% at 5 years. Death-censored analyses also found no difference in pancreas and kidney graft survival rates over 5 years. Higher rejection rate, but the same low CMV infection, and comparable quality of graft function were noted in AA group. AA may not have worse long-term outcomes than CA recipients of SPK with basiliximab induction and tacrolimus (TAC), mycophenolate acid (MFA) and steroid maintenance immunotherapy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1600-6135
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
7
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1815-21
|
pubmed:meshHeading |
pubmed-meshheading:17524073-African Continental Ancestry Group,
pubmed-meshheading:17524073-Antibodies, Monoclonal,
pubmed-meshheading:17524073-European Continental Ancestry Group,
pubmed-meshheading:17524073-Follow-Up Studies,
pubmed-meshheading:17524073-Graft Rejection,
pubmed-meshheading:17524073-Humans,
pubmed-meshheading:17524073-Immunosuppressive Agents,
pubmed-meshheading:17524073-Kidney Transplantation,
pubmed-meshheading:17524073-Louisiana,
pubmed-meshheading:17524073-Pancreas Transplantation,
pubmed-meshheading:17524073-Recombinant Fusion Proteins,
pubmed-meshheading:17524073-Retrospective Studies,
pubmed-meshheading:17524073-Risk Factors,
pubmed-meshheading:17524073-Survival Analysis,
pubmed-meshheading:17524073-Survivors,
pubmed-meshheading:17524073-Time Factors
|
pubmed:year |
2007
|
pubmed:articleTitle |
A comparison of long-term survivals of simultaneous pancreas-kidney transplant between African American and Caucasian recipients with basiliximab induction therapy.
|
pubmed:affiliation |
Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA. rzhang@tulane.edu
|
pubmed:publicationType |
Journal Article
|